Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
Stokman G, van den Hoek AM, Denker Thorbekk D, Pieterman EJ, Skovgård Veidal S, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjaeret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA.
Stokman G, et al. Among authors: pieterman ej.
Liver Int. 2020 Nov;40(11):2860-2876. doi: 10.1111/liv.14643.
Liver Int. 2020.
PMID: 32841505
Free PMC article.